Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of differentiation 19 (CD19)-directed CAR T cell therapy, Breyanzi, met its primary ...

With Monday’s readout, Breyanzi has now shown strong clinically meaningful benefit in five cancer types, BMS wrote in its news release, claiming that this represents “the broadest array of B-cell ...

accounting for up to 30% of cases Bristol Myers Squibb’s (BMS) Breyanzi (lisocabtagene maraleucel) has been recommended by the European Medicines Agency’s human medicines committee to treat follicular ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive ... Rosanna Ricafort, BMS’ head of hematology and cell therapy late development ...

Breyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells. Breyanzi is made from a patient’s own T cells ...

US pharma major Bristol Myers Squibb (NYSE: BMY) has announced that the Phase II TRANSCEND FL trial evaluating Breyanzi (lisocabtagene maraleucel) in adult patients with relapsed or refractory ...

Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but ... the data would give BMS an opportunity to take Breyanzi into so-far uncharted ...

Drawing from their unique experiences, five insights are offered for managing the chimeric antigen receptor (CAR) T cell therapy journey as a caregiver. Breyanzi, a prescription medicine ...